Chronopharmacology and Drug Timing
Circadian rhythms influence enzyme activity, receptor expression, and target organ physiology throughout the 24-hour day — meaning the same dose of a drug can have different efficacy and toxicity profiles depending on when it is taken.
Circadian clocks and pharmacology
The mammalian circadian clock is driven by a transcription-translation feedback loop involving core clock genes (CLOCK, BMAL1, PER, CRY) that generate ~24-hour oscillations in gene expression throughout the body. Nearly every tissue has a local clock synchronised by the central suprachiasmatic nucleus (SCN) in the hypothalamus.
Pharmacologically relevant processes with strong circadian variation include:
- Hepatic CYP enzyme activity — CYP3A4, CYP2E1, and others vary 2–5-fold across the day. See our CYP450 guide
- Gastric acid secretion — peaks nocturnally, affecting oral drug absorption for acid-labile drugs
- Renal GFR and tubular secretion — higher during the day, lower at night; affects elimination of renally cleared drugs
- Blood pressure and heart rate — diurnal pattern with morning surge and nocturnal dip
- Cortisol and ACTH — peak at ~6–8am; critical for corticosteroid therapy timing
- Plasma protein binding — albumin and α1-acid glycoprotein levels show modest diurnal variation, affecting free drug fractions for highly bound drugs. See protein binding glossary
Comprehensive background: Lévi & Schibler, Annual Review of Pharmacology (PubMed) ↗ and NCBI chronopharmacology overview ↗.
Clinical examples by drug class
Evening dosing recommended for short-acting statins (simvastatin, lovastatin). Long-acting agents (atorvastatin, rosuvastatin) — any time. See DailyMed simvastatin label ↗.
Morning surge targets morning dosing in most guidelines. Bedtime dosing may improve nocturnal BP control but evidence is mixed — TIME trial found no MACE difference. See BP medications guide.
Morning dosing mimics cortisol rhythm, reduces HPA suppression. Modified-release (Lodotra) timed at 10pm for 2am release targets nocturnal RA inflammation. See NCBI HPA axis ↗.
Chronotherapy with peak delivery at 4am reduces mucositis while maintaining tumour efficacy. Best evidence in colorectal cancer. See Lévi et al. Lancet Oncol (PubMed) ↗.
PPIs require active proton pumps; efficacy is best when taken 30–60 minutes before the first meal of the day when the most pumps are in active state. Nocturnal acid breakthrough can be managed by a second evening dose in refractory GERD.
Evening dosing of slow-release NSAIDs (diclofenac, indomethacin) may better target nocturnal and early-morning inflammatory pain peaks in rheumatoid arthritis. GI risk remains at any dose time — see our NSAID GI safety update.
Chronopharmacology and TDM sampling
Circadian variation in drug concentrations can confound therapeutic drug monitoring (TDM) interpretation if samples are not drawn at the protocol-specified time. Aminoglycosides, vancomycin, and tacrolimus all have trough concentrations that vary by time of day in some patients — particularly those with significant circadian renal function oscillations.
Always collect TDM samples at steady state and at the defined time point (typically trough, just before the next dose) to ensure interpretability against published therapeutic ranges. See our TDM guide, trough level glossary, and steady-state glossary. Background: PubMed: circadian TDM ↗.